MX2021002295A - Variantes de proteinas recombinantes. - Google Patents
Variantes de proteinas recombinantes.Info
- Publication number
- MX2021002295A MX2021002295A MX2021002295A MX2021002295A MX2021002295A MX 2021002295 A MX2021002295 A MX 2021002295A MX 2021002295 A MX2021002295 A MX 2021002295A MX 2021002295 A MX2021002295 A MX 2021002295A MX 2021002295 A MX2021002295 A MX 2021002295A
- Authority
- MX
- Mexico
- Prior art keywords
- amino acid
- acid modification
- recombinant protein
- protein variants
- acid sequence
- Prior art date
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 6
- 230000004048 modification Effects 0.000 abstract 6
- 238000012986 modification Methods 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 102000004856 Lectins Human genes 0.000 abstract 2
- 108090001090 Lectins Proteins 0.000 abstract 2
- 108010038196 saccharide-binding proteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/178—Lectin superfamily, e.g. selectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4726—Lectins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporciona una proteína lectina modificada que tiene al menos una modificación de aminoácido en una secuencia de aminoácidos de la SEQ ID NO. 1 o en una secuencia de aminoácidos que tiene al menos 60 % de homología con esta. La modificación de aminoácido se selecciona de uno o más de los siguientes: al menos una modificación de aminoácido en un sitio de unión del carbohidrato; 5 al menos una modificación de aminoácido en el extremo N-terminal; al menos una modificación de aminoácido en la posición 76; o al menos una modificación de aminoácido en la posición 44 u 89. La proteína lectina modificada no consiste en la secuencia de aminoácidos de ninguna de las SEQ ID NO: 2 a 4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201821032765 | 2018-08-31 | ||
| PCT/IB2019/057314 WO2020044296A2 (en) | 2018-08-31 | 2019-08-30 | Recombinant protein variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002295A true MX2021002295A (es) | 2021-04-28 |
Family
ID=68344911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002295A MX2021002295A (es) | 2018-08-31 | 2019-08-30 | Variantes de proteinas recombinantes. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11965003B2 (es) |
| EP (1) | EP3844183A2 (es) |
| JP (1) | JP7453213B2 (es) |
| KR (1) | KR20210052449A (es) |
| CN (1) | CN113383015B (es) |
| AU (1) | AU2019330367B2 (es) |
| BR (1) | BR112021003628A2 (es) |
| CA (1) | CA3108842A1 (es) |
| EA (1) | EA202190240A1 (es) |
| MA (1) | MA53498A (es) |
| MX (1) | MX2021002295A (es) |
| SG (1) | SG11202101391WA (es) |
| WO (1) | WO2020044296A2 (es) |
| ZA (1) | ZA202100859B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3118053A1 (en) * | 2018-11-19 | 2020-05-28 | Unichem Laboratories Ltd | Combination of chemotherapy with recombinant s. rolfsii lectin |
| WO2021005500A1 (en) | 2019-07-09 | 2021-01-14 | Unichem Laboratories Ltd | Stable formulations of recombinant proteins |
| CN115515619A (zh) * | 2020-05-07 | 2022-12-23 | 联合化学实验室有限公司 | 抗癌蛋白 |
| BR112023013635A2 (pt) * | 2021-01-07 | 2023-12-05 | Unichem Lab Ltd | Proteína lectina para tratamento e prevenção de doenças neurodegenerativas |
| WO2023281432A1 (en) | 2021-07-08 | 2023-01-12 | Unichem Laboratories Ltd | Recombinant proteins, compositions and methods of stabilization thereof |
| AU2022336409A1 (en) * | 2021-08-30 | 2024-02-15 | Unichem Laboratories Limited | Protein compositions for the treatment of inflammatory diseases |
| US20240383950A1 (en) | 2021-10-01 | 2024-11-21 | Unichem Laboratories Limited | Recombinant glycan binding proteins and its use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2430041B1 (en) * | 2009-02-18 | 2018-10-31 | Unichem Laboratories Limited | Cancer cell binding recombinant lectins with antitumor activity and method of preparation |
| WO2014203261A2 (en) | 2010-02-02 | 2014-12-24 | Unichem Laboratories Ltd. | Recombinant lectin and method of preparing thereof |
| SG11201401956XA (en) * | 2011-11-01 | 2014-10-30 | Nat Inst Of Advanced Ind Scien | Undifferentiated cell detection method and complex carbohydrate detection method |
| SG11201601999UA (en) * | 2013-09-25 | 2016-04-28 | Pronutria Inc | Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control |
| WO2015054507A1 (en) * | 2013-10-10 | 2015-04-16 | Pronutria, Inc. | Nutritive polypeptide production systems, and methods of manufacture and use thereof |
-
2019
- 2019-08-30 WO PCT/IB2019/057314 patent/WO2020044296A2/en unknown
- 2019-08-30 US US17/272,090 patent/US11965003B2/en active Active
- 2019-08-30 MX MX2021002295A patent/MX2021002295A/es unknown
- 2019-08-30 CA CA3108842A patent/CA3108842A1/en active Pending
- 2019-08-30 JP JP2021510408A patent/JP7453213B2/ja active Active
- 2019-08-30 EA EA202190240A patent/EA202190240A1/ru unknown
- 2019-08-30 MA MA053498A patent/MA53498A/fr unknown
- 2019-08-30 CN CN201980054953.7A patent/CN113383015B/zh active Active
- 2019-08-30 BR BR112021003628-8A patent/BR112021003628A2/pt unknown
- 2019-08-30 SG SG11202101391WA patent/SG11202101391WA/en unknown
- 2019-08-30 EP EP19794640.3A patent/EP3844183A2/en active Pending
- 2019-08-30 KR KR1020217005356A patent/KR20210052449A/ko active Pending
- 2019-08-30 AU AU2019330367A patent/AU2019330367B2/en active Active
-
2021
- 2021-02-08 ZA ZA2021/00859A patent/ZA202100859B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020044296A2 (en) | 2020-03-05 |
| ZA202100859B (en) | 2022-07-27 |
| EA202190240A1 (ru) | 2021-08-09 |
| US20210317171A1 (en) | 2021-10-14 |
| AU2019330367B2 (en) | 2024-11-21 |
| BR112021003628A2 (pt) | 2021-05-18 |
| JP7453213B2 (ja) | 2024-03-19 |
| US11965003B2 (en) | 2024-04-23 |
| EP3844183A2 (en) | 2021-07-07 |
| SG11202101391WA (en) | 2021-03-30 |
| AU2019330367A1 (en) | 2021-03-11 |
| CN113383015B (zh) | 2023-06-20 |
| MA53498A (fr) | 2021-07-07 |
| CN113383015A (zh) | 2021-09-10 |
| JP2021534776A (ja) | 2021-12-16 |
| KR20210052449A (ko) | 2021-05-10 |
| CA3108842A1 (en) | 2020-03-05 |
| WO2020044296A3 (en) | 2020-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002295A (es) | Variantes de proteinas recombinantes. | |
| EA038402B9 (ru) | Аденовирусные полинуклеотиды и полипептиды | |
| ES2668967T3 (es) | Inmunógenos de Escherichia coli con solubilidad mejorada | |
| BR112017019625A2 (pt) | udp-glicosiltransferases | |
| MX2008009493A (es) | Peptido novedoso y uso del mismo. | |
| BR112021021912A2 (pt) | Nova nuclease omni-50 crispr | |
| EA201491049A1 (ru) | Противораковый слитый белок | |
| MX2016004579A (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
| PH12013500714A1 (en) | Anticancer fusion protein | |
| CY1123997T1 (el) | Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου | |
| MY195726A (en) | Steviol Glycoside Transport | |
| MX2019008056A (es) | Agonistas del receptor pac1 (maxcaps) y usos de estos. | |
| MX2018008293A (es) | Factor de von willebrand mutado. | |
| WO2019094938A3 (en) | Methods and compositions for the treatment of wounds | |
| EP4043558A3 (en) | Kaurenoic acid hydroxylases | |
| MY187334A (en) | Xylanase | |
| BR112022012057A2 (pt) | Novos métodos de entrega celular | |
| MX2017008505A (es) | Composicion. | |
| MX2015009867A (es) | Mutantes del factor x. | |
| MX2021013702A (es) | Subunidad s2 modificada de la proteina de espicula de coronavirus. | |
| BR112021006248A2 (pt) | cepa mutante de trichoderma reesei e métodos para produzir uma proteína e para produzir uma celulase | |
| BRPI0715331B8 (pt) | polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo | |
| PH12020551339A1 (en) | MUTANTá-GLUCOSIDASE | |
| EA201590431A1 (ru) | Пшеница с новыми аллелями rht-b1 | |
| MX2020013569A (es) | Proteína novedosa con propiedades antiinflamatorias. |